KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Capital Expenditures (2016 - 2025)

Thermo Fisher Scientific's Capital Expenditures history spans 17 years, with the latest figure at $465.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 3.12% year-over-year to $465.0 million, compared with a TTM value of $1.5 billion through Dec 2025, up 8.93%, and an annual FY2025 reading of $1.5 billion, up 8.93% over the prior year.
  • Capital Expenditures for Q4 2025 was $465.0 million at Thermo Fisher Scientific, up from $404.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $831.0 million in Q4 2021, with the low at $272.0 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $458.5 million, with a median of $461.5 million recorded in 2023.
  • Year-over-year, Capital Expenditures skyrocketed 148.22% in 2021 and then tumbled 43.87% in 2023.
  • Tracing TMO's Capital Expenditures over 5 years: stood at $831.0 million in 2021, then tumbled by 33.81% to $550.0 million in 2022, then fell by 26.36% to $405.0 million in 2023, then increased by 18.52% to $480.0 million in 2024, then decreased by 3.12% to $465.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Capital Expenditures are $465.0 million (Q4 2025), $404.0 million (Q3 2025), and $294.0 million (Q2 2025).